Logo
Euro Gen GHK Cu, 50mg

Euro Gen GHK Cu, 50mg

Euro-Gen

Research chemical / peptide reagent
  • Supplied and labelled as a research Use Only peptide Copper complex, not as a medicinal product, medical device, cosmetic or food.
  • Not authorised or licensed by the MHRA, EMA, FDA or other regulatory agencies for any therapeutic or cosmetic indication.
  • Use is governed by general chemical and biological safety regulations and institutional policies applicable to laboratory reagents in the relevant jurisdiction.
  • Researchers and institutions are responsible for ensuring that any use of GHK Cu complies with local laws, ethics approvals and, where relevant, anti Doping and professional practice codes.
Copper tripeptide complex (GHK-Cu) for in vitro research

Description

Euro-Gen GHK-Cu, 50mg is a synthetic research-grade copper tripeptide supplied as a lyophilised powder in a sealed vial, intended strictly for in vitro testing and laboratory research. GHK-Cu is the naturally occurring copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine (GHK), originally isolated from human plasma and also present in saliva and urine. The GHK peptide has a high affinity for copper(II) and forms a small, highly diffusible complex that can modulate copper uptake and distribution in biological systems. In experimental models, GHK-Cu has been shown to promote wound healing, stimulate collagen, elastin and glycosaminoglycan synthesis, support angiogenesis and nerve outgrowth, and exert antioxidant and anti-inflammatory effects. It is also widely used in cosmetic science as a reparative and anti-aging ingredient, though the Euro-Gen product is marketed exclusively as a research reagent and is not approved for therapeutic, cosmetic or veterinary use.

Bnefits

  • Provides a defined 50 mg quantity of synthetic GHK-Cu complex per vial for reproducible in vitro and preclinical research.
  • GHK-Cu (glycyl-L-histidyl-L-lysine–copper complex) is a well-characterised, naturally occurring copper peptide with extensive literature in wound-healing, skin regeneration and tissue-remodelling research.
  • Useful as a tool compound to study copper homeostasis, extracellular matrix synthesis (collagen, elastin, glycosaminoglycans), angiogenesis, nerve regeneration, antioxidant defence and anti-inflammatory signalling.
  • Preclinical and cosmetic-science studies have associated GHK-Cu with improved skin firmness, reduced fine lines, enhanced hair and scalp condition, and accelerated tissue repair, providing multiple translational research angles.
  • The small size and strong copper-binding properties of GHK-Cu make it a convenient model for investigating copper transport, signalling and gene-expression modulation in cell and tissue systems.
  • Supplied as a lyophilised research-grade peptide-copper complex intended for controlled laboratory reconstitution and experimentation; clearly labelled as research use only, helping to prevent inadvertent clinical or cosmetic use.

Indications

  • No approved therapeutic indications; Euro-Gen GHK-Cu, 50mg is not licensed as a medicine, cosmetic or medical device.
  • Intended exclusively for in vitro and preclinical research involving copper peptide GHK-Cu and related pathways.
  • Suitable for studies on skin and soft-tissue regeneration, wound healing, extracellular matrix biology, angiogenesis and neurogenesis in appropriate experimental models.
  • Applicable to investigations of oxidative stress, inflammation, gene-expression modulation and copper homeostasis in cell culture and animal models under proper ethical approval.
  • Not for human or veterinary injection, ingestion, inhalation, topical application, or any other route of bodily administration.

Composition

  • Active research ingredient: Copper peptide GHK-Cu (copper(II) complex of glycyl-L-histidyl-L-lysine).
  • Tripeptide GHK (one-letter sequence): Gly-His-Lys.
  • Tripeptide empirical formula: C14H24N6O4; molecular weight ≈ 340.38 g/mol (peptide alone).
  • GHK-Cu complex empirical formula: C14H22CuN6O4 (monocopper complex).
  • Primary IUPAC name (for GHK): 6-amino-2-[[2-[(2-aminoacetyl)amino]-3-(1H-imidazol-5-yl)propanoyl]amino]hexanoic acid.
  • CAS Registry Number (GHK): 49557-75-7; CAS Registry Number (GHK-Cu complex): 89030-95-5.
  • May contain trace lyophilisation excipients (e.g. mannitol, salts or buffers) as stabilisers; specifics are typically listed on the technical datasheet rather than retail listing.
  • No solvent, bacteriostatic agent or diluent is included; these must be supplied separately by the end user.

Formulation

  • Lyophilised (freeze-dried) GHK-Cu copper tripeptide complex in a sterile, sealed glass vial containing a nominal 50 mg of active complex.
  • Research-grade purity (typically vendor-stated high purity, e.g. ≥98–99% by HPLC) suitable for analytical, biochemical and cell-based assays.
  • Designed for reconstitution with appropriate sterile laboratory-grade diluents (e.g. bacteriostatic water, sterile saline, or assay buffer) under aseptic conditions.
  • Formulated and labelled strictly as a research reagent; not formulated as a pharmaceutical dosage form, topical cosmetic, or injectable for clinical use.

Packaging

  • Single 50 mg lyophilised GHK-Cu vial with rubber stopper and crimped cap, labelled with product name (Euro-Gen GHK-Cu, 50mg) and Euro-Gen branding.
  • Outer secondary packaging (e.g. cardboard carton or padded mailer) used for protection during shipping by Express Peptides or Derma Filler Ltd.
  • Online product pages provide description, pricing, research-use-only disclaimer and basic handling guidance rather than a patient information leaflet, reflecting its non-clinical status.

Usage

  • For in vitro testing and laboratory research use only; to be handled exclusively by suitably qualified and authorised laboratory personnel.
  • Do not inject, ingest, inhale or apply to humans or animals; any bodily administration is explicitly prohibited and outside the product’s intended scope.
  • Before use, visually inspect the unopened vial for integrity of the container and lyophilised cake; do not use if the vial is cracked, the seal compromised or contents appear moist/discoloured.
  • Reconstitute the lyophilised peptide-copper complex with an appropriate sterile laboratory-grade diluent according to institutional SOPs and the requirements of the planned experiment (target concentration, buffer composition, pH).
  • Use aseptic technique during reconstitution and sampling to prevent contamination and to maintain experimental reliability.
  • If solutions are to be stored, prepare aliquots to avoid repeated freeze–thaw cycles, label clearly (compound name, concentration, diluent, date, operator) and record the batch/lot number in laboratory documentation.
  • Dispose of unused reconstituted solutions, vials, needles, syringes and other contaminated materials as chemical/biological laboratory waste in accordance with institutional policies and local regulations.
  • Do not rely on marketing or online product descriptions as medical or cosmetic guidance; GHK-Cu in this format is supplied purely as a research reagent and is not approved for therapeutic or aesthetic treatments.

Contraindications

  • Any use involving administration to humans or animals (e.g. injection, ingestion, inhalation, topical use) is contraindicated and outside the stated research-only purpose.
  • Should not be used as a substitute for licensed medicines or regulated cosmetic products in the treatment of wounds, aging skin, hair loss, pulmonary disease or any other condition.
  • Not suitable for laboratories without appropriate facilities, safety equipment, training and waste-disposal systems for handling synthetic peptides and copper complexes.
  • Personnel with known hypersensitivity to peptides, copper compounds or any excipients should minimise exposure and follow occupational health recommendations.
  • Should not be used for doping, bodybuilding or performance enhancement, nor for DIY aesthetic procedures, as this falls outside research use and may contravene medical and anti-doping regulations.

Adverse Effects

  • No formal adverse-effect profile exists for this commercial preparation in humans or animals, as it is not intended for administration.
  • Accidental laboratory exposure (e.g. skin or eye contact, inhalation of dust/aerosol, or incidental ingestion) may cause non-specific irritation or sensitisation; standard laboratory first-aid measures (thorough rinsing, fresh air, medical evaluation if needed) should be followed.
  • Unauthorised self-administration or clinical use of research-grade GHK-Cu may carry significant and unpredictable risks, including contamination, incorrect dosing, local or systemic reactions and unknown long-term safety; such practices are strongly discouraged.
  • Copper-containing compounds can be toxic at inappropriate doses or in susceptible individuals; unregulated use outside laboratory settings may disrupt copper homeostasis and contribute to oxidative stress or organ dysfunction.
  • Laboratory personnel should refer to institutional risk assessments for peptides and metal complexes and use appropriate PPE (gloves, lab coat, eye protection) when handling.

Storage Conditions

  • Store unopened vials in a cool, dry place protected from direct light and moisture; many laboratories store lyophilised peptides refrigerated (2–8 °C) or frozen (≤ −20 °C) according to internal SOPs.
  • Avoid prolonged exposure to elevated temperatures and repeated temperature cycling; do not use if there are signs of degradation or container damage.
  • After reconstitution, store solutions according to institutional guidelines (e.g. aliquoted and kept at 2–8 °C for short-term use or ≤ −20 °C for longer-term storage) and minimise freeze–thaw cycles.
  • Keep vials and reconstituted solutions out of reach of unauthorised personnel and clearly segregated from licensed medicinal products, foods and cosmetics.
  • Dispose of expired or compromised material as laboratory waste in compliance with local regulations and institutional policies.

Duration

Not applicable. Euro-Gen GHK-Cu, 50mg is a research reagent with no authorised treatment regimen or dosing schedule in humans or animals; any therapeutic, bodybuilding, cosmetic or self-experimental use would be outside its intended scope.

Onset

Not applicable in a clinical context. In experimental systems, the timing and magnitude of observed biological effects depend on model type, concentration, exposure protocol and endpoints measured, and cannot be extrapolated to human therapeutic onset or efficacy.

Browse more Research chemical / peptide reagent

Top Treatments

Top Cities in the UK